Johnson & Johnson Statement on New Hampshire Opioid Settlement Agreement

NEW BRUNSWICK, NJ, September 1, 2022 - Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies (collectively, the “Company”) today announced a settlement agreement with the State of New Hampshire and its participating subdivisions resolving their opioid-related claims against the Company. This settlement will resolve the upcoming trial scheduled to begin on September 12, 2022 in Merrimack County, New Hampshire. The settlement will directly support local community efforts to seek meaningful progress in addressing the opioid crisis in New Hampshire. Under the terms of the agreement, the Company will pay $39 million, as well as an additional approximately $1.5 million, for which the Company will be reimbursed from the nationwide settlement fund because New Hampshire did not participate in that settlement. This settlement is not an admission of liability or wrongdoing and marks continued progress in resolving opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. The Company will continue to defend against any litigation that the final agreement does not resolve.The Company’s actions relating to the marketing and promotion of important prescription opioid medications were appropriate and responsible. DURAGESIC®, NUCYNTA® and NUCYNTA® ER accounted for less than one percent of total opioid prescriptions in New Hampshire and the U.S. since launch. The Company no longer sells prescription opioid medica...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news